Journal of Bioequivalence & Bioavailability

Visweswaran Navaratnam

Publications

• Research Article
  Pharmacokinetics and Comparative Bioavailability of Artesunate and Mefloquine Administered Separately or as a Fixed Combination Product to Healthy Volunteers and Patients with Uncomplicated Plasmodium falciparum Malaria.
  Author(s): Piero Olliaro, Surash Ramanathan, Michel Vaillant, Stephanie E Reuter, Allan M Evans, Srivicha Krudsood, Sornchai Looareesuwan, Jean-René Kiechel, Walter RJ Taylor and Visweswaran NavaratnamPiero Olliaro, Surash Ramanathan, Michel Vaillant, Stephanie E Reuter, Allan M Evans, Srivicha Krudsood, Sornchai Looareesuwan, Jean-René Kiechel, Walter RJ Taylor and Visweswaran Navaratnam
  
  Purpose: The current World Health Organization recommendation for the treatment of uncomplicated Plasmodium falciparum malaria is with artemisinin-based combination therapy. Artesunate and mefloquine combination therapy has achieved consistently high efficacy rates and reduced malaria morbidity; however, the current standard treatment regimen is complex and may be difficult to comply with outside of a research setting. Consequently, an artesunate mefloquine fixed dose oral co-formulation has been developed and is now registered in Brazil. This study was conducted in order to assess the pharmacokinetics and comparative bioavailabilities of artesunate and mefloquine administered as separate products and the new co-formulated product. Methods: The pharmacokinetics of artesunate, dihydroartemisinin, the artesunate metabolite and predominant species and mefloquine were assessed in a single.. View More»
  DOI: 10.4172/jbb.1000032

  Abstract PDF